{"id":24468,"date":"2025-07-01T21:00:00","date_gmt":"2025-07-01T15:30:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=24468"},"modified":"2025-07-01T17:31:45","modified_gmt":"2025-07-01T12:01:45","slug":"chronic-spontaneous-urticaria-csu-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment","title":{"rendered":"Towards a Promising Future: Unveiling Advancements in Chronic Spontaneous Urticaria (CSU) Treatment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0e358e8f242\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0e358e8f242\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment\/#What_is_Chronic_Spontaneous_Urticaria\" >What is Chronic Spontaneous Urticaria?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment\/#Diagnosing_the_Itch_Chronic_Spontaneous_Urticaria\" >Diagnosing the Itch: Chronic Spontaneous Urticaria&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment\/#Current_Approaches_to_Chronic_Spontaneous_Urticaria_Treatment\" >Current Approaches to Chronic Spontaneous Urticaria Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment\/#Advancements_in_the_Field_of_Chronic_Spontaneous_Urticaria_Treatment_Space\" >Advancements in the Field of Chronic Spontaneous Urticaria Treatment Space<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment\/#Unfolding_Emerging_Refractory_Chronic_Spontaneous_Urticaria_Treatment_Options\" >Unfolding Emerging Refractory Chronic Spontaneous Urticaria Treatment Options<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment\/#Pipeline_Highlights_Leading_Upcoming_Drugs_in_CSU\" >Pipeline Highlights: Leading Upcoming Drugs in CSU<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment\/#Challenges_Despite_Pipeline_Progress\" >Challenges Despite Pipeline Progress<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment\/#Market_Outlook\" >Market Outlook<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Chronic urticaria is a persistent skin condition marked by recurrent, itchy wheals or hives that last for more than six weeks and can persist for over a year. As per DelveInsight\u2019s analysts, approximately <strong>4.7 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-epidemiology-forecast\"><strong>prevalent cases of chronic urticaria<\/strong><\/a> were reported across the <strong>7MM in 2024,<\/strong> underscoring a significant disease burden. Based on the classification of urticaria, it can be broadly divided into chronic spontaneous urticaria (CSU), where the cause is unknown, and chronic inducible urticaria (CIndU), which is triggered by specific stimuli. Understanding the types of chronic urticaria is crucial for accurate diagnosis and the selection of appropriate urticaria treatment strategies. While CSU treatment often involves antihistamines and advanced biologics, chronic inducible urticaria treatment typically focuses on identifying and avoiding known triggers, in line with evolving urticaria treatment.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-chronic-spontaneous-urticaria\"><span class=\"ez-toc-section\" id=\"What_is_Chronic_Spontaneous_Urticaria\"><\/span><strong><strong>What is Chronic Spontaneous Urticaria?<\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Chronic spontaneous urticaria (CSU),<\/strong> also referred to as chronic idiopathic urticaria, is a debilitating form of CSU skin disease characterized by the spontaneous activation of mast cells and basophils, which release pro-inflammatory mediators that trigger urticaria symptoms. Key features include persistent itching, hives, and in some cases, angioedema, lasting longer than six weeks. The hallmark presentation involves red, itchy, swollen lesions or \u201cwheals\u201d, which may vary in size from a few millimeters to several centimeters and often merge to form larger patches. As one of the more severe types of chronic urticaria, CSU significantly impacts quality of life, with patients experiencing up to 30% reduced job performance, in addition to considerable direct and indirect healthcare costs. Given its burden, chronic spontaneous urticaria treatment remains a clinical priority, with evolving urticaria treatment guidelines 2024 focusing on symptom control, long-term management, and improving patient well-being.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-diagnosing-the-itch-chronic-spontaneous-urticaria-nbsp\"><span class=\"ez-toc-section\" id=\"Diagnosing_the_Itch_Chronic_Spontaneous_Urticaria\"><\/span><strong><strong>Diagnosing the Itch: Chronic Spontaneous Urticaria&nbsp;<\/strong><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Chronic spontaneous urticaria<\/strong> disproportionately affects women, who are <strong>twice as likely as men<\/strong> to be diagnosed. Most patients develop symptoms between <strong>20 and 40 years of age<\/strong>, with spontaneous urticaria presenting as recurring hives and\/or angioedema without a known trigger. <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-market\">Diagnosing CSU <\/a>involves a detailed <strong>medical history<\/strong>, <strong>physical examination<\/strong>, and, in some cases, additional tests such as <strong>blood work, allergy testing<\/strong>, or <strong>skin biopsies<\/strong> to rule out other urticaria causes like allergic reactions or infections.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/chronic-spontaneous-urticaria-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150643\/Chronic-Spontaneous-Urticaria-infographic-1024x194.webp\" alt=\"Chronic Spontaneous Urticaria infographic\" class=\"wp-image-24479\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150643\/Chronic-Spontaneous-Urticaria-infographic-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150643\/Chronic-Spontaneous-Urticaria-infographic-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150643\/Chronic-Spontaneous-Urticaria-infographic-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150643\/Chronic-Spontaneous-Urticaria-infographic-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150643\/Chronic-Spontaneous-Urticaria-infographic-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150643\/Chronic-Spontaneous-Urticaria-infographic-1568x297.webp 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150643\/Chronic-Spontaneous-Urticaria-infographic.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>Diagnostic tools such as the <strong>Urticaria Activity Score (UAS)<\/strong>, <strong>Urticaria Control Test (UCT)<\/strong>, <strong>Chronic Urticaria Quality of Life questionnaire<\/strong>, and <strong>Urticaria Severity Score (USS)<\/strong> are essential for assessing disease activity and treatment response. The autologous serum skin test (ASST) is often used in CSU to detect auto-reactivity, a hallmark of the disease. In some cases, autoantibodies against IgE or its high-affinity receptor (Fc\u03b5RI) are implicated, confirming the autoimmune nature of CSU in certain patients. This complexity underlines the importance of personalized diagnostic approaches in chronic spontaneous urticaria treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-approaches-to-chronic-spontaneous-urticaria-treatment\"><span class=\"ez-toc-section\" id=\"Current_Approaches_to_Chronic_Spontaneous_Urticaria_Treatment\"><\/span><strong>Current Approaches to Chronic Spontaneous Urticaria Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-market\">Chronic spontaneous urticaria treatment<\/a> is often complex, requiring a personalized and stepwise approach to control symptoms and reduce flare-ups. The typical CSU treatment algorithm begins with second-generation H1-antihistamines as the first-line therapy, given their ability to block histamine receptors and alleviate common symptoms like itching, redness, and swelling.<\/p>\n\n\n\n<p>For patients unresponsive to standard doses, up-dosing of second-generation H1-antihistamines up to fourfold is recommended as the second step. If symptoms persist,<strong> XOLAIR (omalizumab)<\/strong>, a monoclonal antibody and the only currently approved targeted therapy for CSU, is used as the third-line treatment. However, around one-third of patients remain symptomatic despite omalizumab.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"388\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01172946\/Chronic-Spontaneous-Urticaria-Treatment-Algorithm-1024x388.png\" alt=\"Chronic Spontaneous Urticaria Treatment Algorithm\" class=\"wp-image-32621\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01172946\/Chronic-Spontaneous-Urticaria-Treatment-Algorithm-1024x388.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01172946\/Chronic-Spontaneous-Urticaria-Treatment-Algorithm-300x114.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01172946\/Chronic-Spontaneous-Urticaria-Treatment-Algorithm-150x57.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01172946\/Chronic-Spontaneous-Urticaria-Treatment-Algorithm-768x291.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01172946\/Chronic-Spontaneous-Urticaria-Treatment-Algorithm-1536x582.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01172946\/Chronic-Spontaneous-Urticaria-Treatment-Algorithm-2048x776.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>In such refractory cases, cyclosporine may be considered, especially for individuals with severe disease not responding to any antihistamine dose or biologic therapy. Beyond this, a range of <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-market\">off-label chronic urticaria treatments<\/a>, including <strong>corticosteroids, immunosuppressants, antidepressants, leukotriene receptor antagonists, sulfasalazine, methotrexate, IV immunoglobulins, interferon, phototherapy, <\/strong>and <strong>plasmapheresis<\/strong>, can be explored based on individual case needs and treatment response.<\/p>\n\n\n\n<p>Notably, the American Academy of Allergy, Asthma, and Immunology (AAAAI) still includes first-generation H1-antihistamines in its treatment pathway, whereas most global practices recommend avoiding them due to sedation and side effects, highlighting variations in treatment strategies across regions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-advancements-in-the-field-of-chronic-spontaneous-urticaria-treatment-space\"><span class=\"ez-toc-section\" id=\"Advancements_in_the_Field_of_Chronic_Spontaneous_Urticaria_Treatment_Space\"><\/span><strong>Advancements in the Field of Chronic Spontaneous Urticaria Treatment Space<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Over the past few decades, substantial progress has been made in the understanding, diagnosis, and treatment of <strong>chronic spontaneous urticaria (CSU)<\/strong>. Evolving scientific insights, updated classifications, and evidence-based guidelines have contributed to more precise disease management. Below are the major milestones and improvements shaping the current CSU landscape:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Improved Disease Understanding<\/strong><strong><br><\/strong>Research has deepened our grasp of CSU\u2019s underlying biology, highlighting roles for mast cells, basophils, autoimmune responses, and mediators like IgG anti-Fc\u03b5RI\u03b1, alongside toll-like receptors and coagulation pathways.<\/li>\n\n\n\n<li><strong>Updated Classification of Urticaria<br><\/strong>Modern classification distinguishes chronic spontaneous urticaria (CSU) from chronic inducible urticaria (CIndU), which includes forms like cholinergic, aquagenic, and contact urticaria. The outdated terms \u201cchronic idiopathic\u201d and \u201cphysical urticaria\u201d have been refined to reflect clearer mechanistic and trigger-based distinctions.<\/li>\n\n\n\n<li><strong>Development of Diagnostic &amp; Monitoring Tools<br><\/strong>Both prospective and retrospective tools are now used to assess symptom severity and quality of life:\n<ul class=\"wp-block-list\">\n<li><strong>UAS7<\/strong>: Tracks daily wheals and itching over 7 days.<\/li>\n\n\n\n<li><strong>UCT<\/strong>, <strong>USS<\/strong>, and <strong>CU-Q2oL<\/strong>: Evaluate disease control and impact retrospectively.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Refined Clinical Guidelines &amp; Treatment Algorithms<br><\/strong>International guidelines (e.g., EAACI\/GA\u00b2LEN\/EDF\/WAO) promote a <strong>step-wise CSU treatment pathway<\/strong>:\n<ul class=\"wp-block-list\">\n<li><strong>First-line<\/strong>: Second-generation H1-antihistamines.<\/li>\n\n\n\n<li><strong>Second-line<\/strong>: Up-dosing up to fourfold.<\/li>\n\n\n\n<li><strong>Third-line<\/strong>: <strong>Omalizumab<\/strong> for antihistamine-refractory cases.<\/li>\n\n\n\n<li><strong>Fourth-line<\/strong>: <strong>Cyclosporine<\/strong> in severe, resistant CSU.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Regional Divergence in Guidelines<br><\/strong>The AAAAI still includes first-generation antihistamines, in contrast to most global bodies that discourage their use due to sedative effects.<\/li>\n\n\n\n<li><strong>Evidence-Based Practice with GRADE Methodologies<br><\/strong>Newer guidelines now integrate <strong>GRADE frameworks<\/strong>, helping standardize diagnosis, optimize CSU treatment, and guide clinical decision-making.<\/li>\n\n\n\n<li><strong>Ongoing Gaps<br><\/strong>Despite progress, the field still lacks validated biomarkers to fully explain pathogenesis or predict chronic spontaneous urticaria treatment response.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-unfolding-emerging-refractory-chronic-spontaneous-urticaria-treatment-options\"><span class=\"ez-toc-section\" id=\"Unfolding_Emerging_Refractory_Chronic_Spontaneous_Urticaria_Treatment_Options\"><\/span><strong>Unfolding Emerging Refractory Chronic Spontaneous Urticaria Treatment Options<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Despite a structured, guideline-based ladder approach to <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-epidemiology-forecast\"><strong>chronic spontaneous urticaria treatment<\/strong><\/a>, a significant proportion of patients\u2014nearly one-third\u2014remain symptomatic even after using <strong>omalizumab<\/strong>, the only currently approved biologic. Conventional therapies like <strong>second-generation H1-antihistamines<\/strong> and omalizumab often fail to achieve complete symptom control, particularly in patients experiencing severe <strong>itching, wheals, and angioedema<\/strong>. These limitations highlight a persistent unmet need and fuel the development of <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-pipeline-insight\"><strong>upcoming chronic spontaneous urticaria drugs<\/strong><\/a> that promise better efficacy and novel mechanisms of action.These investigational therapies are primarily targeted toward <strong>refractory CSU<\/strong>, aiming to go beyond symptom relief and restore long-term disease control. Several agents now in late-stage development offer hope to patients who are unresponsive to current treatments and signal a shift toward <strong>precision medicine in urticaria care<\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"254\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01173044\/Chronic-Spontaneous-Urticaria-Emerging-Drugs-1024x254.png\" alt=\"Chronic-Spontaneous-Urticaria-Emerging-Drugs\" class=\"wp-image-32622\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01173044\/Chronic-Spontaneous-Urticaria-Emerging-Drugs-1024x254.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01173044\/Chronic-Spontaneous-Urticaria-Emerging-Drugs-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01173044\/Chronic-Spontaneous-Urticaria-Emerging-Drugs-150x37.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01173044\/Chronic-Spontaneous-Urticaria-Emerging-Drugs-768x191.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01173044\/Chronic-Spontaneous-Urticaria-Emerging-Drugs-1536x381.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/01173044\/Chronic-Spontaneous-Urticaria-Emerging-Drugs-2048x509.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pipeline_Highlights_Leading_Upcoming_Drugs_in_CSU\"><\/span><strong>Pipeline Highlights: Leading Upcoming Drugs in CSU<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Barzolvolimab (CDX-0159) \u2013 Celldex Therapeutics<br><\/strong> A novel KIT inhibitor, barzolvolimab is a humanized monoclonal antibody targeting the KIT receptor tyrosine kinase, which regulates mast cell survival and activity, key in CSU pathology.\n<ul class=\"wp-block-list\">\n<li>As one of the most promising <strong>upcoming CSU drugs<\/strong>, it demonstrated strong disease control and quality-of-life improvements in <strong>Phase II trials<\/strong>.<\/li>\n\n\n\n<li>Key updates were shared at the <strong>AAAAI 2025 Annual Meeting<\/strong>, and in <strong>May 2025<\/strong>, long-term 76-week data were accepted for a late-breaking oral presentation at EAACI 2025.<\/li>\n\n\n\n<li>Currently being evaluated in <strong>Phase III<\/strong>, barzolvolimab could emerge as a viable alternative for omalizumab-resistant patients.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Remibrutinib (LOU064) \u2013 Novartis<br><\/strong>Among the most anticipated upcoming chronic spontaneous urticaria drugs, remibrutinib is a highly selective Bruton\u2019s Tyrosine Kinase (BTK) inhibitor that blocks histamine release and mast cell degranulation.\n<ul class=\"wp-block-list\">\n<li>In the pivotal <strong>REMIX-1 and REMIX-2 Phase III trials<\/strong>, it met all primary endpoints and demonstrated rapid, durable symptom relief through Week 52 in patients unresponsive to antihistamines.<\/li>\n\n\n\n<li>Novartis presented compelling efficacy and quality-of-life data at the <strong>2025 AAAAI\/WAO and AAD meetings<\/strong>.<\/li>\n\n\n\n<li><strong>Regulatory filings <\/strong>are planned for early 2025, with <strong>FDA approval anticipated in the second half of 2025<\/strong>. Pediatric trials are also ongoing.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-challenges-despite-pipeline-progress\"><span class=\"ez-toc-section\" id=\"Challenges_Despite_Pipeline_Progress\"><\/span><strong>Challenges Despite Pipeline Progress<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>While these <strong>upcoming CSU drugs<\/strong> hold promise, most are still being developed as <strong>add-on or rescue therapies<\/strong>, rather than <strong>first-line curative options<\/strong>. Additionally, they still require robust long-term safety and efficacy data to support regulatory approvals and widespread adoption.<\/p>\n\n\n\n<p>There are also notable gaps in the broader CSU landscape:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Limited epidemiological data, especially among <strong>children and adolescents<\/strong><\/li>\n\n\n\n<li>Poor differentiation between <strong>CSU and chronic inducible urticaria (CIndU)<\/strong> in many clinical studies<\/li>\n\n\n\n<li>A lack of <strong>validated biomarkers<\/strong> to accurately diagnose and predict treatment response<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Market_Outlook\"><\/span><strong>Market Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>According to DelveInsight\u2019s analysis, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-market\"><strong>chronic spontaneous urticaria market size<\/strong><\/a> in the 7MM (US, EU5, Japan) was approximately <strong>USD 2 billion in 2024<\/strong>. Driven by the launch of these upcoming chronic spontaneous urticaria therapies, along with improved diagnosis and rising awareness, the market is projected to grow significantly over the forecast period (2025\u20132034).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1691989967902\"><strong class=\"schema-faq-question\"><strong>1. What is chronic spontaneous urticaria?<\/strong><\/strong> <p class=\"schema-faq-answer\">Chronic spontaneous urticaria (CSU) is a type of chronic urticaria that occurs without a clear external trigger. It typically lasts more than six weeks and can persist for over a year. As a long-term inflammatory skin condition, it significantly affects quality of life and is often associated with psychiatric comorbidities. The condition falls under the broader urticaria classification, which also includes chronic inducible urticaria (CIndU), triggered by physical stimuli.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1691989980182\"><strong class=\"schema-faq-question\"><strong>2. What causes chronic spontaneous urticaria?<\/strong><\/strong> <p class=\"schema-faq-answer\">The exact cause of CSU is not fully understood, but it is often linked to autoimmune responses, where autoantibodies activate mast cells and basophils, leading to hives and swelling. Other factors like stress, infections, and medications may worsen the condition. As opposed to acute urticaria, which is usually allergic, CSU is more complex and persistent.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1691989985487\"><strong class=\"schema-faq-question\"><strong>3. How is chronic spontaneous urticaria diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">Diagnosis is mostly clinical, based on symptom duration and the presence of hives or angioedema. Doctors may conduct blood tests, thyroid screening, and allergy tests to rule out other causes. Tools like the autologous serum skin test (ASST) and basophil histamine release assay help identify autoimmunity in CSU.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1691989995274\"><strong class=\"schema-faq-question\"><strong>4. How is chronic spontaneous urticaria treated?<\/strong><\/strong> <p class=\"schema-faq-answer\">CSU treatment follows a stepwise approach, starting with second-generation H1-antihistamines. If symptoms persist, the dose may be increased up to fourfold. For patients unresponsive to antihistamines, omalizumab is recommended as a third-line option. In severe or refractory cases, csu treatments may include cyclosporine or other off-label immunomodulatory.<\/p> <\/div> <\/div>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/30154222\/chronic-spontaneous-urticaria-Market-Outlook-1024x194.png\" alt=\"Chronic Spontaneous Urticaria Market Outlook\" class=\"wp-image-32607\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/30154222\/chronic-spontaneous-urticaria-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/30154222\/chronic-spontaneous-urticaria-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/30154222\/chronic-spontaneous-urticaria-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/30154222\/chronic-spontaneous-urticaria-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/30154222\/chronic-spontaneous-urticaria-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/30154222\/chronic-spontaneous-urticaria-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Chronic urticaria is a persistent skin condition marked by recurrent, itchy wheals or hives that last for more than six weeks and can persist for over a year. As per DelveInsight\u2019s analysts, approximately 4.7 million prevalent cases of chronic urticaria were reported across the 7MM in 2024, underscoring a significant disease burden. Based on the [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":24472,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19119,21183,21182,21179,21181,21177,21180,21178,4799],"industry":[17225],"therapeutic_areas":[17237],"class_list":["post-24468","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-chronic-spontaneous-urticaria","tag-chronic-spontaneous-urticaria-market","tag-chronic-spontaneous-urticaria-patients","tag-chronic-spontaneous-urticaria-symptoms","tag-chronic-spontaneous-urticaria-therapies","tag-chronic-spontaneous-urticaria-treatment","tag-chronic-spontaneous-urticaria-treatment-patterns","tag-csu","tag-dupixent","industry-pharmaceutical","therapeutic_areas-dermatology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Changing Landscape of Chronic Spontaneous Urticaria Treatment<\/title>\n<meta name=\"description\" content=\"Although there has been tremendous investment in chronic spontaneous urticaria treatment, there are still gray areas that require attention.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changing Landscape of Chronic Spontaneous Urticaria Treatment\" \/>\n<meta property=\"og:description\" content=\"Although there has been tremendous investment in chronic spontaneous urticaria treatment, there are still gray areas that require attention.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-01T15:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150107\/chronic-spontaneous-urticaria-csu-treatment.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changing Landscape of Chronic Spontaneous Urticaria Treatment","description":"Although there has been tremendous investment in chronic spontaneous urticaria treatment, there are still gray areas that require attention.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment","og_locale":"en_US","og_type":"article","og_title":"Changing Landscape of Chronic Spontaneous Urticaria Treatment","og_description":"Although there has been tremendous investment in chronic spontaneous urticaria treatment, there are still gray areas that require attention.","og_url":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-07-01T15:30:00+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150107\/chronic-spontaneous-urticaria-csu-treatment.webp","type":"image\/webp"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment","url":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment","name":"Changing Landscape of Chronic Spontaneous Urticaria Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150107\/chronic-spontaneous-urticaria-csu-treatment.webp","datePublished":"2025-07-01T15:30:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Although there has been tremendous investment in chronic spontaneous urticaria treatment, there are still gray areas that require attention.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989967902"},{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989980182"},{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989985487"},{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989995274"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150107\/chronic-spontaneous-urticaria-csu-treatment.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150107\/chronic-spontaneous-urticaria-csu-treatment.webp","width":1200,"height":800,"caption":"chronic-spontaneous-urticaria-csu-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989967902","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989967902","name":"1. What is chronic spontaneous urticaria?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Chronic spontaneous urticaria (CSU) is a type of chronic urticaria that occurs without a clear external trigger. It typically lasts more than six weeks and can persist for over a year. As a long-term inflammatory skin condition, it significantly affects quality of life and is often associated with psychiatric comorbidities. The condition falls under the broader urticaria classification, which also includes chronic inducible urticaria (CIndU), triggered by physical stimuli.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989980182","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989980182","name":"2. What causes chronic spontaneous urticaria?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The exact cause of CSU is not fully understood, but it is often linked to autoimmune responses, where autoantibodies activate mast cells and basophils, leading to hives and swelling. Other factors like stress, infections, and medications may worsen the condition. As opposed to acute urticaria, which is usually allergic, CSU is more complex and persistent.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989985487","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989985487","name":"3. How is chronic spontaneous urticaria diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Diagnosis is mostly clinical, based on symptom duration and the presence of hives or angioedema. Doctors may conduct blood tests, thyroid screening, and allergy tests to rule out other causes. Tools like the autologous serum skin test (ASST) and basophil histamine release assay help identify autoimmunity in CSU.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989995274","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/chronic-spontaneous-urticaria-csu-treatment#faq-question-1691989995274","name":"4. How is chronic spontaneous urticaria treated?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"CSU treatment follows a stepwise approach, starting with second-generation H1-antihistamines. If symptoms persist, the dose may be increased up to fourfold. For patients unresponsive to antihistamines, omalizumab is recommended as a third-line option. In severe or refractory cases, csu treatments may include cyclosporine or other off-label immunomodulatory.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/08\/14150107\/chronic-spontaneous-urticaria-csu-treatment-300x200.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic spontaneous urticaria market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic spontaneous urticaria patients<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic spontaneous urticaria symptoms<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic spontaneous urticaria therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chronic spontaneous urticaria treatment patterns<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CSU<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dupixent<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria<\/span>","<span class=\"advgb-post-tax-term\">chronic spontaneous urticaria market<\/span>","<span class=\"advgb-post-tax-term\">chronic spontaneous urticaria patients<\/span>","<span class=\"advgb-post-tax-term\">chronic spontaneous urticaria symptoms<\/span>","<span class=\"advgb-post-tax-term\">chronic spontaneous urticaria therapies<\/span>","<span class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria Treatment<\/span>","<span class=\"advgb-post-tax-term\">chronic spontaneous urticaria treatment patterns<\/span>","<span class=\"advgb-post-tax-term\">CSU<\/span>","<span class=\"advgb-post-tax-term\">Dupixent<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 months ago","modified":"Updated 11 months ago"},"absolute_dates":{"created":"Posted on Jul 1, 2025","modified":"Updated on Jul 1, 2025"},"absolute_dates_time":{"created":"Posted on Jul 1, 2025 9:00 pm","modified":"Updated on Jul 1, 2025 5:31 pm"},"featured_img_caption":"chronic-spontaneous-urticaria-csu-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=24468"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24468\/revisions"}],"predecessor-version":[{"id":32623,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/24468\/revisions\/32623"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/24472"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=24468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=24468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=24468"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=24468"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=24468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}